We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
+20.43%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$869M
AUM Growth
-$37.3M
Cap. Flow
-$52.6M
Cap. Flow %
-6.05%
Top 10 Hldgs %
62.94%
Holding
54
New
3
Increased
9
Reduced
7
Closed
6

Top Buys

Rank Stock Value
1
VECT
VectivBio Holding AG Ordinary Shares
VECT
+$18.8M
2
GERN icon
Geron
GERN
+$9.06M
3
ATXS
Astria Therapeutics
ATXS
+$7.02M
4
PCVX icon
Vaxcyte
PCVX
+$6.87M
5
CMPX icon
Compass Therapeutics
CMPX
+$6.21M

Top Sells

Rank Stock Value
1
HRMY icon
Harmony Biosciences
HRMY
+$43.7M
2
RLMD icon
Relmada Therapeutics
RLMD
+$26.4M
3
ASND icon
Ascendis Pharma A/S
ASND
+$15.1M
4
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$8.67M
5
STSA
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
+$7.39M

Sector Composition

Rank Sector Weight
1 Healthcare 98.63%
2 Materials 1.37%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IOBT
26
DELISTED
IO Biotech
IOBT
$6.94M 0.8%
3,015,545
– –
MRUS
27
DELISTED
Merus
MRUS
$6.79M 0.78%
438,590
-3,410
-0.8% -$60K
DYN icon
28
Dyne Therapeutics
DYN
$4.92B
$6.7M 0.77%
577,642
– –
WHWK
29
Whitehawk Therapeutics
WHWK
$205M
$6.54M 0.75%
509,572
– –
KALV
30
DELISTED
KalVista Pharmaceuticals
KALV
$5.79M 0.67%
856,008
-677,551
-44% -$3.63M
ARWR icon
31
Arrowhead Research
ARWR
$12.6B
$5.57M 0.64%
137,411
– –
BCAB icon
32
BioAtla
BCAB
$5.56M
$5.26M 0.61%
+12,744
New +$5.29M
CINC
33
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
$5.18M 0.6%
421,635
+72,398
+21% +$1.73M
BOLT icon
34
Bolt Biotherapeutics
BOLT
$7.78M
$5.03M 0.58%
193,565
– –
IOVA icon
35
Iovance Biotherapeutics
IOVA
$1.99B
$4.19M 0.48%
655,057
– –
DBVT
36
DBV Technologies
DBVT
$836M
$4.14M 0.48%
270,888
– –
OLMA icon
37
Olema Pharmaceuticals
OLMA
$1.01B
$4.14M 0.48%
1,689,515
– –
VRNA
38
DELISTED
Verona Pharma
VRNA
$3.64M 0.42%
4,249,918
– –
ALGS icon
39
Aligos Therapeutics
ALGS
$29.5M
$3.38M 0.39%
141,881
– –
SERA icon
40
Sera Prognostics
SERA
$75.6M
$2.34M 0.27%
1,856,011
– –
GRCL
41
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
$2.21M 0.25%
961,358
-1
-0% -$3
CDXS icon
42
Codexis
CDXS
$156M
$1.81M 0.21%
388,144
– –
ASLN
43
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$1.02M 0.12%
71,023
– –
RZLT icon
44
Rezolute
RZLT
$473M
$1.01M 0.12%
489,473
– –
IMUX icon
45
Immunic
IMUX
$192M
$833K 0.1%
+63,218
New +$1.72M
UTRS
46
DELISTED
Minerva Surgical, Inc. Common Stock
UTRS
$495K 0.06%
110,783
– –
QTTB icon
47
Q32 Bio
QTTB
$477M
$466K 0.05%
20,559
– –
DTIL icon
48
Precision BioSciences
DTIL
$194M
$167K 0.02%
4,675
– –
ASND icon
49
Ascendis Pharma A/S
ASND
$16.1B
– –
-146,025
Closed -$15.1M
CLDX icon
50
Celldex Therapeutics
CLDX
$3.12B
– –
-198,983
Closed -$5.59M
1
2
3

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.05% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
MB
MidFirst Bank Oklahoma City, Oklahoma $1.21B AUM
CCM
Condor Capital Management Martinsville, New Jersey $1.2B AUM 13.18% 1-Year Est. Return
LWIC
Leith Wheeler Investment Counsel Vancouver, British Columbia, Canada $1.21B AUM 12.04% 1-Year Est. Return
TIM
Tortoise Investment Management White Plains, New York $1.21B AUM 13.04% 1-Year Est. Return

Vivo Capital's Q4 2022 Portfolio in Review

As of Q4 2022, Vivo Capital held 54 positions worth $869M, down 4.1% from $906M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Vivo Capital withdrew a net $52.6M in Q4 2022, closing 6 positions and reducing 7 holdings. Its most notable exit was Relmada Therapeutics, an estimated $26.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Materials.

Against the trend, Vivo Capital opened a new position in VectivBio Holding AG Ordinary Shares worth $20.2M.

  • Vivo Capital's largest Q4 2022 buy was VectivBio Holding AG Ordinary Shares: 2,333,300 shares worth $20.2M.
  • Vivo Capital added most to Geron in Q4 2022, an estimated $9.06M increase.
  • Vivo Capital's biggest Q4 2022 reduction was Harmony Biosciences, cutting an estimated $43.7M.
  • Vivo Capital fully exited Relmada Therapeutics in Q4 2022, selling an estimated $26.4M.
  • Vivo Capital's ten largest holdings make up 63% of its $869M portfolio in Q4 2022.
  • Vivo Capital opened 3 new positions and closed 6 in Q4 2022.
  • Vivo Capital's portfolio value fell 4.1% quarter-over-quarter to $869M.

Based on Vivo Capital's 13F filing for Q4 2022, filed 13 Feb 2023.